[Value of molecular markers for administration of anticoagulant therapy after heart valve replacement].
In a prospective study, 39 patients following aortic or mitral valve replacement underwent investigation of molecular markers (prothrombin fragment F1+2, Factor II) in the initial phase of oral anticoagulation therapy (OAT). The results demonstrate that, despite INR being in the depicted range, the levels of the molecular markers remained high, indicating an increased risk of thromboembolic events. This leads to the conclusion that molecular markers are superior to INR in the monitoring of the early phase of OAT.
Dahm
M
M
Herzchirurgie, Universitätsklinik Mainz.
Lotz
J
J
Hafner
G
G
Oelert
H
H
Prellwitz
W
W
D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001021:Aortic Valve / Q000601:surgery; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D019934:International Normalized Ratio; D008943:Mitral Valve / Q000601:surgery; D010446:Peptide Fragments / Q000378:metabolism*; D010644:Phenprocoumon / Q000008:administration & dosage*; D011183:Postoperative Complications / Q000097:blood / Q000517:prevention & control*; D011446:Prospective Studies; D011516:Prothrombin / Q000378:metabolism*; D012680:Sensitivity and Specificity; D013923:Thromboembolism / Q000097:blood / Q000517:prevention & control*
D000925:Anticoagulants; D010446:Peptide Fragments; C045879:prothrombin fragment 1.2; D011516:Prothrombin; D010644:Phenprocoumon
Stellenwert der molekularen Marker in der Einstellung der Antikoagulantientherapie nach Herzklappenersatz.